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USE OF MODIFIED PYRIMIDINE
COMPOUNDS TO PROMOTE STEM CELL
MIGRATION AND PROLIFERATION

While the synaptic connections involved in neural circuits
are continuously altered throughout the life of the individual,
due to synaptic plasticity and cell death, neurogenesis (the
generation of new neurons) was thought to be complete early
in the postnatal period. The discovery ofMNSCs in the adult
brain (see, e.g., Alvarez-Buylla et al., 1997, J. Neurobiol 33:
585-601; Gould et al., 1999, Science 286: 548-552) has significantly changed the theory on neurogenesis, as the presence of MNSCs in the adult brain suggests that regeneration
of neurons can occur throughout life. Nevertheless, age,
physical and biological trauma or neurodegenerative diseaseassociated loss of brain function, herein referred to as a "neurological deficit," can far outweigh any potential restorative
effects due to endogenous neurogenesis. As a result, upregulated or stimulated proliferation of endogenous MNSCs
as well as transplantation ofMNSCs are potentially valuable
treatments for those suffering from the loss of, or loss of
appropriate, brain function due to age, physical and biological trauma or neurodegenerative disease (i.e., a neurological
deficit). No such treatments are known in the art.
Due to the advancing average age of the population, and
concomitantly increased incidence of neurological deficit
that accompanies advancing age, treatment of neurodegenerative diseases has become a major concern. Such diseases,
including Alzheimer's disease, Huntington's chorea and Parkinson's disease, have been linked to neuronal degeneration
at specific locations in the brain, leading to the inability of the
brain region to synthesize and release neurotransmitters that
are vital to neuronal signaling.
Neurodegeneration also encompasses many conditions
and diseases, age-related or not, that result in neuronal loss.
These conditions include CNS trauma, such as ischemia
(stroke) and epilepsy, as well as diseases that result in neuronal loss, including amyotrophic lateral sclerosis and cerebra! palsy.
Many such neurological deficits are localized to particular
regions of the brain. Degeneration in a brain region known as
the basal ganglia can lead to diseases with varied and different
cognitive and motor symptoms, depending on the exact locati on of the lesion. The basal ganglia consists of many separate
regions, including the striatum (which consists of the caudate
and putamen), the globus pallidus, the substantia nigra, substantia innominata, ventral pallidum, nucleus basalis ofMeynert, ventral tegmental area and the subthalamic nucleus.
Degeneration in the basal ganglia can lead to motor deficits. For example, Huntington's chorea is associated with
degeneration of neurons in the striatum, which leads to involuntary jerking movements. Degeneration of a small region
called the subthalamic nucleus is associated with violent
flinging movements of the extremities in a condition called
ballismus, while degeneration in the putamen and globus
pallidus are associated with a condition of slow writhing
movements or athetosis. In Parkinson's disease, degeneration
is seen in another area of the basal ganglia, the substantia
nigra par compacta. This area normally sends dopaminergic
connections to the dorsal striatum, which are important in
regulating movement. Therapy for Parkinson's disease has
centered upon restoring dopaminergic activity to this circuit.
Alzheimer's disease patients exhibit a profound cellular
degeneration of the forebrain and cerebral cortex. Further, a
localized area of the basal ganglia, the nucleus basalis of
Meynert, appears to be selectively degenerated. This nucleus
normally sends cholinergic projections to the cerebral cortex
that are thought to participate in cognitive functions including
memory.
The objective of most CNS therapies is to regain the particular chemical function or enzymatic activity lost due to

RELATED APPLICATIONS
This application is a division of U.S. Ser. No. 13/028,325,
filed Feb. 16, 2011, now U.S. Pat. No. 8,273,756, which is a
division of U.S. Ser. No. 12/053,429 filed Mar. 21, 2008,
which is a continuation ofU.S. Ser. No. 10/341,683, filed Jan.
14, 2003, This application is related to which claims priority
to U.S. Provisional Patent Applications, Ser. No. 60/348,473,
filed Jan. 14, 2002, and Ser. No. 60/357,783, filed Feb. 19,
2002, and Ser. No. 60/376,257, filed Apr. 29, 2002, and Ser.
No. 60/381,138, filed May 8, 2002, and Ser. No. 60/404,361,
filed Aug. 19, 2002, and Ser. No. 60/430,381, filed Dec. 2,
2002, the disclosures of each of which are expressly incorporated by reference herein.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH
This invention was made with support from the U.S. Govermnent through the National Institutes of Health, Grant No.
R03-AG19874. Accordingly, the government has certain
rights in this invention.
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BACKGROUND
Stem cells are often defined as self-renewing and multipotent, with the ability to generate diverse types of differentiated
cells. As such, they show promise in the treatment of neurological and corporal disorders (also referred to as neurological and corporal "deficits"), or any loss or diminishment of
tissue function due to age, disease, trauma or other factor.
However, such treatments have faced significant hurdles that
have yet to be substantially overcome.
NSCs and Neurological Deficits
Because an important focus of stem cell replacement therapies has been neurological disorders, neural stem cells, and
particularly fetal neural stem cells, have been a major
research target. During development of the central nervous
system (CNS), multipotent neural stem cells (MNSCs), also
known as multi potent precursor cells (MPCs ), or tissue-specific neural stem cells (NSCs), proliferate, giving rise to transiently dividing progenitor cells that eventually differentiate
into the cell types that compose the adult brain, including
neurons, astrocytes and oligodendrocytes. NSCs have been
isolated from several mammalian species, including mice,
rats, pigs and humans. See, e.g., International Application,
Publication Nos. WO 93/01275, WO 94/09119, WO
94/10292, WO 94/16718 and Cattaneo et al., 1996, Mo!.
Brain. Res. 42: 161-66. NSCs from the embryonic and adult
rodent central nervous system (CNS) have been isolated and
further propagated in vitro in a variety of culture systems.
See, e.g., Frolichsthal-Schoeller et al., 1999, NeuroReport
10: 345-351; Doetsch et al., 1999, Cell 97: 703-716. NSCs
from the human fetal brain have been cultured using serumfree medium supplemented with epidermal growth factor
(EGF) and/or basic fibroblast growth factor (bFGF). See, e.g.,
Svendsen et al., 1998, J. Neurosci. Meth. 85: 141-152; Carpenter et al., 1999, Exp. Neural. 158: 265-278. NSCs cultured
utilizing these serum-free, mitogen-supplemented methods
generally form substantially undifferentiated, clustered
aggregates. Upon removal of the mitogen( s) and provision of
a substrate, these neural stem cells differentiate into neurons,
astrocytes and oligodendrocytes.
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cellular degeneration. Administration of pharmaceutical
compositions has been the main treatment for CNS dysfunction though this type of treatment has complications, including the limited ability to transport drugs across the bloodbrain barrier, and drug-tolerance acquired by patients to
whom these drugs are administered for long periods.
Transplantation of multipotent stem cells may avert the
need not only for constant drug administration, but also for
complicated drug delivery systems necessitated by the bloodbrain barrier. In practice, however, significant limitations
have been found in this technique as well. First, cells used for
transplantation that carry cell surface molecules of a differentiated cell from a donor can induce an immune reaction in
the recipient, a problem that is exacerbated by the physical
damage caused by injection of cells directly into the affected
area of the brain. In addition, the neural stem cells must be at
a developmental stage where they are able to form normal
neural connections with neighboring cells. For these reasons,
initial studies on neurotransplantation centered on the use of
fetal cells.
Mammalian fetal brain tissue has proven to have reasonable survival characteristics upon immediate transplantation.
Increased survival capability of fetal neurons is thought to be
due to the reduced susceptibility of fetal neurons to anoxia
compared to adult neurons. An additional factor favoring
survival of fetal cells is their lack of cell surface markers,
whose presence may lead to rejection of grafted tissue from
adults. However, although the brain is considered an immunologically privileged site, some rejection of even fetal tissue
can occur. Therefore, the ability to use heterologous fetal
tissue is limited by tissue rejection and the resulting need for
immunosuppressant drug administration.
The use of large quantities of aborted fetal tissue presents
other difficulties as well. Fetal CNS tissue is composed of
more than one cell type, and thus is not a well-defined tissue
source. In addition, it may be unlikely that an adequate and
constant supply of fetal tissue would be available for transplantation. For example, in the treatment of MPTP-induced
Parkinsonism, tissue from as many as 6 to 8 fetuses can be
required for successful implantation into the brain of a single
patient. There is also the added problem of the potential for
contamination during fetal tissue preparation. Since this tissue may already be infected with a bacteria or virus, expensive diagnostic testing is required for each fetus used. Even
comprehensive diagnostic testing might not uncover all
infected tissue. For example, there can be no guarantee that a
sample is HIV-free, because antibodies to the virus are generally not present until several weeks after infection.
In addition to fetal tissue, there are other potential sources
of tissue for neurotransplantation, including cell lines and
genetically engineered cell types, but both sources have serious limitations. Cell lines are immortalized cells that are
derived, inter alia, by transformation of normal cells with an
oncogene or by the culturing of cells in vitro with altered
growth characteristics. Moreover, adverse immune response
potential, the use of retroviruses to immortalize cells, the
potential for the reversion of these cells to an amitotic state,
and the lack of response by these cells to normal growthinhibiting signals make such cell lines sub-optimal for widespread use.
Another approach to neurotransplantation involves the use
of genetically engineered cell types or gene therapy. However, there still exists a risk of inducing an immune reaction
with these cells. In addition, retrovirus mediated transfer may
result in other cellular abnormalities. Also, cell lines produced by retrovirus-mediated gene transfer have been shown
to gradually inactivate their transferred genes following

transplantation and further may also not achieve normal neuronal connections with the host tissue.
Currently available transplantation approaches suffer from
significant drawbacks. The inability in the prior art of the
transplant to fully integrate into the host tissue, and the lack of
availability of suitable cells in unlimited amounts from a
reliable source for grafting are significant limitations ofneurotransplantation. Studies utilizing intra-tissue injection of
dissociated and partially differentiated NSCs have shown
little promise (see, e.g., Benninger et al., 2000, Brain Pathol.
10: 330-341; Blakemore et al. 2000, Cell Transplant 9: 289294; Rosser et al., 2000, Eur. J. Neurosci. 12: 2405-2413;
Rubio et al., 2000, Mo!. Cell. Neurosci. 16: 1-13). The results
have generally been poor because, among many considerations, the dissociation of clusters ofNSCs is known to cause
immediate senescence ofNSCs and increase the vulnerability
ofNSCs in culture. See, e.g., Svendsen et al., 1998, J. Neurosci. Meth. 85: 141-152. Further, regardless of adverse
immune responses provoked by foreign tissue being introduced into the brain, the trauma caused by the physical introduction of cells directly into the damaged area can induce the
recruitment of immune cells by the host that can eliminate the
transplanted cells. Thus, significant problems with the use of
NSCs to ameliorate neurological deficits remain. As
described herein, neurological deficits also include non-brain
tissues such as, for example, the eye and spinal cord.
A "corporal deficit" is a disorder caused by a wide variety
of diseases and injuries, resulting in trauma, malfunction,
degeneration or loss of muscle such as, for example, cardiac
muscle due to myocardial infarction. Other examples include
malfunction, degeneration or loss of other cells and tissues
apart from those discussed in the neurological deficit section
above such as, for example, internal organs. For example,
liver function can be adversely affected by, among other
things, disease (e.g., cirrhosis or hepatitis), trauma or age. The
problems described above in using NSCs to remedy neurological deficits of the brain also apply to neurological deficits
in other tissues, such as the eye, and corporal deficits.
There exists a need in the art for improved methods for
increasing the number of multi potent cells in an animal and
thereby increasing the reservoir of remedial capacity conferred by multipotent stem cells in tissues. There exists a need
to stimulate proliferation, migration or both proliferation and
migration of endogenous and exogenously introduced mammalian multipotent stem cells in vivo as well as mammalian
multipotent stem cells in vitro. There exists a need for cells
stimulated to proliferate, migrate or both proliferate and
migrate, as well as pharmaceutical compositions for treating
a neurological deficit or corporal deficit comprising such
stimulated cells. Further, there exists a need in the art for
methods of administration of such cells stimulated to proliferate, migrate or both proliferate and migrate and pharmaceutical compositions thereof. Still further, there exists a need for
methods for treating an animal having a neurological or corporal deficit.
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Disclosed herein are methods for stimulating proliferation,
migration or both proliferation and migration of mammalian
stem cells in vivo and in vitro and cells produced by those
methods. In particular, provided are reagents and methods for
efficiently proliferating stem cells in an animal in need
thereof and producing stem cells that can be re-introduced
into an animal in need thereof to alleviate neurological disorders.
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In a first aspect, provided is a method of stimulating proliferation, migration or both proliferation and migration of
endogenous and exogenous mammalian stem cells in vivo. In
one embodiment, the method comprises the step of introducing to a mammal an effective amount ofa pyrimidine derivative of:

embodiments, the inventive method comprises administering
autologous or non-autologous stem cells, wherein the autologous or non-autologous stem cells are stimulated to proliferate and migrate to an area of tissue damage, differentiate in a
tissue-specific manner and function in a manner that reduces
the neurological or corporal deficit. In further related embodiments, the more developmentally potent cells or the autologous stem cells or the non-autologous stem cells administered
with the pyrimidine derivative form a cluster of two or more
cells. In further related embodiments, the more developmentally potent cells or the autologous stem cells or the nonautologous stem cells are derived from a tissue or tissuespecific stem cell. In other embodiments, the stem cell is a
hematopoietic stem cell, a neural stem cell, an epithelial stem
cell, an epidermal stem cell, a retinal stem cell, an adipose
stem cell or a mesenchymal stem cell, any of which can be
obtained from any tissue containing stem cells including but
not limited to zygote, blastocyst, embryo, fetus, infant juvenile or adult, and optionally, a human species of any of the
preceding embodiments, whether naturally occurring or engineered. In certain embodiments, the cluster of two or more of
the more developmentally potent cells or the autologous stem
cells or the non-autologous stem cells comprises less than
about 50 percent redifferentiated cells, or more preferably
less than about 25 percent redifferentiated cells, or even more
preferably less than about 10 percent redifferentiated cells, or
even more preferably less than about 5 percent redifferentiated cells, or even more preferably less than about 1 percent
redifferentiated cells. In related embodiments, the more
developmentally potent cells or the autologous stem cells or
the non-autologous stem cells, in the form of a cluster of two
or more cells in other related embodiments, are administered
by injecting the more developmentally potent cells with a
syringe, inserting the more developmentally potent cells or
the autologous stem cells or the non-autologous stem cells
with a catheter or surgically implanting the said cells. In other,
further related embodiments, the more developmentally
potent cells or the autologous stem cells or the non-autologous stem cells are injected with a syringe, inserted with a
catheter or surgically implanted either to a body cavity that is
fluidly-connected to the area of neurological or corporal deficit or to the area of neurological or corporal deficit. In
embodiments relating to neurological or corporal deficits, the
neurological deficit is optionally caused by a neurodegenerative disease, a traumatic injury, a neurotoxic injury, ischemia,
a developmental disorder, a disorder affecting vision, an
injury or disease of the spinal cord, a demyelinating disease,
an autoimmune disease, an infection, or an inflammatory
disease and the corporal deficit is optionally caused by corporal disease, disorder, injury, trauma, malfunction, degeneration or loss.
In certain embodiments the pyrimidine derivative of formula (I) is MS-818, or 2-piperadino-6-methyl-5-oxo-5,6-dihydro(7H) pyrrolo[2,3-d]pyrimidine maleate (the C4 H4 0 4
maleate salt), as disclosed in U.S. Pat. No. 4,959,368, incorporated by reference herein. In certain in vivo embodiments,
the pyrimidine derivatives of formulae (I) and (II) is administered at a concentration of between about 0.01 mg/kg/day to
50 mg/kg/day, more preferably between about 0.1 mg/kg/day
to 10 mg/kg/day, even more preferably between about 1
mg/kg/day to 5 mg/kg/day, and even more preferably about 3
mg/kg/day. In these embodiments, the pyrimidine derivatives
of formulae (I) and (II) is administered for between about 1
and 60 days, or more preferably between about 1 and 30 days,
ormorepreferablybetweenabout 1and15 days, orevenmore
preferably between about 1 and 10 days, or more preferably
between about 2 and 7 days, or even more preferably about 5
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where R 1 to R 8 independently represent a hydrogen atom,
a lower alkyl group, CH 3 0CH 2 CH 2 - , CH 2 CONH 2 ,
-COCH 3 , -COC 2 H 5 or --CH 2 0COC 2 H 5 ; and
X is =NH,
N-CH 3 , =N--C 2 H 5 , =N-ph,
=N--COOC 2 H 5 , =N-S0 2 CH 3 , =CH 2 , =CHCH 3 ,
=CHC 2 H 5 , ---0- or-S- in which ph stands for a phenyl
group; or a pharmaceutically acceptable salt thereof.
In another aspect, provided is a method of stimulating
proliferation, migration or both proliferation and migration of
exogenous mammalian stem cells in vivo to a mammal that
has had more developmentally potent cells or the autologous
stem cells or the non-autologous stem cells administered
thereto. In one embodiment, the method comprises the step of
introducing to a mammal an effective amount of the pyrimidine derivative of formulae (I) or (II) above or a pharmaceutically acceptable salt thereof.
In another aspect, provided is a method of stimulating
proliferation, migration or both proliferation and migration of
endogenous mammalian stem cells in vitro. In one embodiment, the method comprises the step of contacting a mammalian stem cell with an effective amount of the pyrimidine
derivative of formulae (I) or (II) above or a pharmaceutically
acceptable salt thereof.
In another aspect, provided is a method for treating an
animal with a neurological or corporal deficit. In one embodiment, the method comprises the step of administering an
effective amount of the pyrimidine derivative of formulae (I)
or (II) above, or a pharmaceutically acceptable salt thereof,
wherein the endogenous stem cell population is stimulated to
proliferate and migrate to an area of tissue damage, differentiate in a tissue-specific manner and function in a manner that
reduces the neurological or corporal deficit. In certain
embodiments the inventive methods further comprise the step
of administering more developmentally potent cells, wherein
the more developmentally potent cells are stimulated to proliferate and migrate to an area of tissue damage, differentiate
in a tissue-specific manner and function in a manner that
reduces the neurological or corporal deficit. In related
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days. In certain others of these embodiments, the methods
further comprise the step of administering a growth factor. In
certain embodiments, the growth factor comprises fibroblast
growth factor, epidermal growth factor or a combination
thereof.
In certain in vitro embodiments, the stem cell culture is
contacted with the pyrimidine derivative of formulae (I) or
(II) in an effective amount, or a concentration of between
about 50 nM to 1 mM, or more preferably between about 500
nM to 500 µM, or even more preferably between about 1 µM
to 100 µM, or more preferably between about 5 µM to 7 5 µM
and even more preferably about 50 µM. In these embodiments, the stem cell culture is contacted with pyrimidine
derivatives of formulae (I) and (II) for an effective period, or
between about 1 and 60 days, or more preferably between
about 1 and 30 days, or more preferably between about 1 and
15 days, or even more preferably between about 1 and 10
days, or more preferably between about 2 and 7 days, or even
more preferably about 5 days. In certain others of these
embodiments, the methods further comprise the step of contacting the cell culture with a growth factor. In certain
embodiments, the growth factor comprises fibroblast growth
factor, epidermal growth factor or a combination thereof. In
certain others of these embodiments, the methods further
comprise contacting the stem cell culture with heparin.
In another aspect, provided is cells stimulated for proliferation, migration or both proliferation and migration produced according to the teachings herein. In another aspect,
provided is a pharmaceutical composition for treating a neurological or corporal deficit comprising the cells stimulated
for proliferation, migration or both proliferation and migration produced according to the methods taught herein. In
certain embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
Thus, the present disclosure advantageously provides
methods of stimulating proliferation and migration of mammalian stem cells in vivo and in vitro, cells produced by those
methods, pharmaceutical compositions to treat neurological
and corporal deficits, and methods of administering the cells
and pharmaceutical compositions provided herein.
Specific embodiments will become evident from the following more detailed description of certain preferred
embodiments and the claims.

The methods disclosed herein can act to increase the number
of such exogenously transplanted cells in vivo, as well as
enhance their number while being treated according to the
methods of said co-owned and co-pending application. Further, the methods of the instant disclosure can increase the
abundance of the endogenous NSC population.
FIG. 2 shows typical fluorescent immunohistochemical
photomicrographs of aged rat brain 30 days after transplantation ofMNSCs of the co-owned and co-pending U.S. patent
application referenced above. bIII-tubulin and GFAP immunoreactivity were used as markers for neuron and glia, respectively. (a) MNSCs of the co-owned and co-pending U.S.
patent application migrated into the cortex and differentiated
into neurons as indicated by the bIII-tubulin positive cells
(green), which have morphologies typical of pyramidal cells
in layer IV and V of the parietal cortex. Apical dendrites were
pointed towards to the edge of the cortex. Since the NSCs
were pre-treated with BrdU, the transplanted cells have BrdU
positive nuclei (red). Contrarily, the host cell's nuclei are
counter stained with DAPI (blue). Many cells having BrdU
positive nuclei are observed with bII-tubulin immunoreactivity in layer II and without bIII-tubulin immunoreactivity in
layer III. (b, c) Higher magnification of the parietal cortex in
cortex layer IV: all the bII-tubulin immunoreactive (green)
positive cells show BrdU (red) positive nuclei while many
other host cell's nuclei are stained with only DAPI (blue). (d)
MNSCs according to said co-owned and co-pending U.S.
patent application migrated into the hippocampus and differentiated into bIII-tubulin positive cells (green), in CAI pyramidal cell layer. These bII-tubulin positive cells have BrdU
positive nuclei (red), indicating that these cells originated
from transplanted cells. In contrast, host cell nuclei counter
stained with DAPI (blue) are not bII-tubulin positive. (e) In
the dentate gyrus many fibers were bIII-tubulin positive in
addition to the bII-tubulin positive cells (green) and GFAP
positive sells (red). (f) bII-tubulin positive cells (green) and
GFAP positive cells (red) were found in layer IV and layer III,
respectively. Such a layer of astrocytes was not observed in
normal rats without NSC transplantation. Again, the methods
of the instant disclosure can act to increase the number of such
exogenously transplanted, BrdU-treated cells in vivo, as well
as enhance their number while being treated according to the
methods of the co-owned and co-pending application. The
methods of the instant disclosure can also increase the abundance of the endogenous NSC population.
FIG. 3 shows the effects ofMS-818 on endogenous neural
stem cell populations in the brain. (a) Typical immunohistochemistry (x200) using BrdU (brown, marker for proliferating cells) in a control aged rat cerebral cortex without
MS-818 treatment. (b) Typical immunohistochemistry
(x200) using BrdU in an aged rat cerebral cortex with
MS-818 treatment (3 mg/kg/day, i.p. for 5 days). The number
ofBrdU positive cells is significantly increased after MS-818
treatment. (c) Typical immunohistochemistry (x200) using
BrdU (brown, marker for proliferating cells) in a control aged
rat SVZ without MS-818 treatment. (d) Typical immunohistochemistry (x200) using BrdU in an aged rat SVZ with
MS-818 treatment (3 mg/kg/day, i.p. for 5 days). The number
of BrdU positive cells is increased after MS-818 treatment.
(e) Quantitative analysis of the effects ofMS-818 on a number of BrdU-positive cells in the cortex (a, b ). There was a
7-fold increase in stem cell population after MS-818 treatment.
FIG. 4 shows the effects ofMS-818 on endogenous retinal
stem cell populations. (a) Typical immunohistochemistry
(x400) using BrdU (red, marker for proliferating cells) in
control rat retina without MS-818 treatment. (b) Typical

BRIEF DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the
Office upon request and payment of the necessary fee, pursuant to 37 C.F.R. §1.84.
FIG. 1 shows the effect of transplantation of MNSC
according to the methods of co-owned and co-pending U.S.
patent application, entitled "Novel Mammalian Multipotent
Stem Cells and Compositions, Methods of Preparation and
Methods of Administration Thereof," (Ser. No. 10/345,126,
filed Jan. 14, 2003) on memory score in the Morris water
maze test. (a) Individual memory score before and after transplantation shows improvement in the majority of the animals.
Blue: Aged memory impaired animals, Green: Aged memory
unimpaired animals, Red: Matured animals. (b) Mean of
memory score in each animal group before (narrow striped
bar) and after (black bar) MNSC transplantation shows a
significant improvement in aged memory impaired and
young animals. The animals that received vehicle injection do
not show significant difference in memory score between
before (wide striped bar) and after (hatched) the injection.
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immunohistochemistry (x400) using BrdU in rat retina with
intraocular administration ofMS-818 (10 g/20 µl). The number ofBrdU-positive cells is clearly increased after the treatment.

filed Jan. 14, 2003, or "App. 2." Each application is incorporated herein by reference in their entirety.
As used herein, the term "cluster" refers to a group of two
or more non-terminally differentiated cells. A cluster can
comprise the progeny of a single multipotent stem cell or
small cluster of primary cells.
As used herein, the terms "effective amount" and "therapeutically effective amount" each refer to the amount of
reagent used to support or produce the desired activity. In the
case of the cells stimulated for proliferation, migration or
both proliferation and migration prepared and delivered
according to the provided methods, an effective amount is an
amount necessary to support or produce an observable level
ofone or more biological activities of MSC as set forth herein.
Regarding pyrimidine derivatives, an effective amount can be
between about 0.01 mg/kg/day to 50 mg/kg/day, more preferably between about 0.1 mg/kg/day to 10 mg/kg/day, even
more preferably between about 1 mg/kg/day to 5 mg/kg/day,
and even more preferably about 3 mg/kg/day.
An "effective period" as used herein refers to the time
period necessary for the reagents and cells of the embodiments taught herein to accomplish their specified activities.
For example, cells disclosed herein can be contacted with a
pyrimidine derivative for an effective period to make them
more developmentally potent. An effective period for contact
with a pyrimidine derivatives can be, for example, between
about 1 and 60 days, or more preferably between about 1 and
30 days, or more preferably between about 1 and 15 days, or
even more preferably between about 1 and 10 days, or more
preferably between about 2 and 7 days, or even more preferably about 5 days.
The term "pharmaceutically acceptable carrier" or "physiologically acceptable carrier" as used herein refers to one or
more formulation materials suitable for accomplishing or
enhancing the successful delivery of the pharmaceutical composition of stimulated stem cells prepared and delivered
according to the disclosed methods.
As disclosed in further detail herein, the inventive methods
provide for introducing pyrimidine derivatives of formulae (I)
or (II),

5

DETAILED DESCRIPTION OF PREFERRED
EMBODIMENTS
This provided is methods for stimulating proliferation,
migration or proliferation and migration of endogenous and
exogenous mammalian stem cells in vivo. The disclosure also
provides methods for stimulating proliferation, migration or
proliferation and migration of marmnalian stem cells in vitro.
The method further provides cells produced by the aforementioned methods. More generally, provided is reagents and
methods for efficiently proliferating mammalian stem cells in
an animal in need thereof and producing stem cells that can be
re-introduced into an animal in need thereof to alleviate neurological and corporal disorders.
As used herein, the terms "multipotent neural stem cells
(MNSCs ),""neural stem cells (NSCs ),"and "multi potent precursor cells (MPCs)" refer to undifferentiated, multipotent
cells of the CNS. Such terms are commonly used in the
scientific literature. MNSCs can differentiate into tissue-specific cell types, for example astrocytes, oligodendrocytes, and
neurons when transplanted in the brain. The multipotent cells
are distinguished from natural NSCs by their stimulation for
proliferation, migration or both proliferation and migration
due to treatment by the methods provided herein.
As used herein, a "less developmentally potent cell" is a
cell that is capable oflimited multi-lineage differentiation or
capable of single-lineage, tissue-specific differentiation, for
example, an untreated mesenchymal stem cell can differentiate into, inter alia, osteocytes and chrondrocytes, i.e., cells
of mesenchymal lineage but has only limited ability to differentiate into cells of other lineages (e.g., neural lineage.).
As used herein, a "more developmentally potent cell" is a
cell that is readily capable of differentiating into a greater
variety of cell types than its corresponding less developmentally potent cell. For example, a mesenchymal stem cell can
readily differentiate into osteocytes and chrondrocytes but
has only limited ability to differentiate into neural or retinal
lineage cells (i.e., it is a less developmentally potent cell in
this context). Mesenchymal stem cells treated according to
the methods of the above-referenced co-owned and co-pending U.S. patent application become more developmentally
potent because they can readily differentiate into, for
example, mesenchymal-lineage and neural-lineage cell
types; the plasticity of the cells is increased when treated
according to the methods disclosed herein.
More developmentally potent cell" and "less developmentally potent cell" as used herein are fully disclosed and
claimed in co-owned and co-pending U.S. patent application
entitled "Novel Mammalian Multipotent Stem Cells and
Compositions, Methods of Preparation and Methods of
Administration Thereof," Ser. No. 10/345,126, filed Jan. 14,
2003, or "App. 1."
As used herein, "multipotent stem cells" or "MSCs" refer
to the cells prepared according to the methods disclosed
herein and in co-owned and co-pending U.S. patent application entitled "Novel Marmnalian Multipotent Stem Cells and
Compositions, Methods of Preparation and Methods of
Administration Thereof," Ser. No. 10/345,126, filed Jan. 14,
2003, or "App. 1" and co-owned and co-pending U.S. patent
application entitled "Novel Mammalian Multipotent Neural
Stem Cells and Compositions, Methods of Preparation and
Methods of Administration Thereof," Ser. No. 10/342,616,
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where R 1 to R 8 independently represent a hydrogen atom,
a lower alkyl group, CH 3 0CH 2 CH 2 - , CH 2 CONH 2 ,
--COCH 3 , --COC 2 H 5 or -CH 2 0COC 2 H 5 ; and
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=NH,
N-CH3, =N---C2H5, =N-ph,
=N---COOC 2H 5, =N-S0 2CH 3, =CH 2, =CHCH 3,
=CHC 2H 5, ---0- or-S- in which ph stands for a phenyl
group; or a pharmaceutically acceptable salt thereof to a
mammal in an amount effective to stimulate proliferation,
migration or both proliferation and migration of endogenous
multipotent stem cells in vivo. Endogenous multipotent stem
cells can be of varied origin, inter alia, stem cells ofhematopoietic, neural, mesenchymal, epithelial, epidermal, adipose
and retinal origin, and administration of the pyrimidine
derivatives can be localized to a particular tissue.
The disclosure also provides methods for introducing pyrimidine derivatives, or pharmaceutically suitable salts thereof,
to a mammal in an amount effective to stimulate proliferation,
migration or both proliferation and migration, in vivo, of
exogenous multipotent stem cells introduced to the mammal
before, after or concurrently with the pyrimidine derivative.
Further, a rest period between the introduction of the pyrimidine derivative and the multipotent stem cells can be implemented as necessary to minimize any trauma caused by their
administration. The exogenously introduced multipotent
stem cells can be prepared according to the methods
described in App. 1. or App. 2, and as set forth below.
Both the pyrimidine derivatives and the exogenous multipotent stem cells can be administered by injection with a
syringe, insertion with a catheter or surgical implantation.
The pyrimidine derivatives can be administered at the site of
neurological or corporal deficit, systemically (e.g., intravenously), or in the case of neurological deficits of the brain,
spinal cord or any tissues accessible by cerebral spinal fluid
(CSF), in a brain ventricle. The exogenous multipotent stem
cells can be administered at the site of neurological or corporal deficit, systemically (e.g., intravenously), or in the case of
neurological deficits of the brain, spinal cord or any tissues
accessible by cerebral spinal fluid (CSF), in a brain ventricle.
In another in vivo embodiment, provided is a method for
treating an animal with a neurological or corporal deficit. In
one embodiment, the method can comprise administering an
effective amount of a pyrimidine derivative or pharmaceutically acceptable salt thereof such that the endogenous stem
cell population is stimulated to proliferate and migrate to an
area of tissue damage, differentiate in a tissue-specific manner and function in a manner that reduces the neurological or
corporal deficit. In other embodiments, the inventive method
further comprises the step of administering multi potent stem
cells of App. 1 or App. 2, referenced above, wherein the
exogenous multipotent stem cells are stimulated to proliferate
and migrate to an area of tissue damage, differentiate in a
tissue-specific manner and function in a manner that reduces
the neurological or corporal deficit. Similarly, in related
embodiments, the inventive method can comprises administering autologous or non-autologous stem cells instead of
administering the multipotent stem cells of App. 1 or App. 2,
wherein the autologous or non-autologous stem cells are
stimulated to proliferate and migrate to an area of tissue
damage, differentiate in a tissue-specific manner and function
in a manner that reduces the neurological or corporal deficit.
As an example, tissue-specific stem cells can be isolated from
the eventual recipient or another source, and administered
with the pyrimidine derivative. The isolated cells can be
treated in vitro with the pyrimidine derivative or be left
untreated with the pyrimidine derivative. When the autologous or non-autologous stem cells are administered to the
human or animal with a neurological or corporal deficit, the
cells differentiate in a tissue-specific manner according to
their natural potency. For example, hematopoietic stem cells
have some natural, limited capacity to differentiate into cer-

tain skin cells. According to this embodiment, hematopoietic
stem cells could be isolated from the recipient of another
source and treated before, concurrently, or after administration to the recipient with a pyrimidine derivative. Such cells
are stimulated for proliferation, migration or both proliferation and migration, and differentiate according to the environmental signals they (1) actually encounter and (2) are
capable of naturally responding to. Thus, hematopoietic stem
cells administered to a skin wound with pyrimidine derivative
proliferate and migrate due to the exposure to the pyrimidine
derivative and differentiate according to the environmental
signals they encounter in the wound and are capable of
responding to. Immunosuppressant drugs can be used to suppress any immunorejection of non-autologous cells. Similarly, mesenchymal stem cells can be isolated from an animal
in need of additional mesenchymal stem cells. Limited numbers of cells can be isolated and treated with pyrimidine
derivatives according to the methods disclosed herein. Such
cells can be stimulated to proliferation, migration or both due
to exposure to the pyrimidine derivative. Large numbers of
cells can be propagated in vitro and reintroduced to the donor
or other, non-autologous recipient.
The multi potent stem cells can be administered in the form
a cluster of two or more cells. The multipotent stem cells can
be derived from a tissue or tissue-specific stem cell, for
example, a hematopoietic stem cell, a neural stem cell, an
epithelial stem cell, an epidermal stem cell, a retinal stem cell,
an adipose stem cell and a mesenchymal stem cell, any of
which can be obtained from any tissue containing stem cells
including but not limited to zygote, blastocyst, embryo, fetus,
infant juvenile or adult, and optionally, a human species of
any of the preceding embodiments, whether naturally occurring or engineered.
When utilizing "more developmentally potent" multipotent stem cells or autologous stem cells or non-autologous
stem cells in a cluster of two or more cells, the cluster of
multipotent stem cells can comprise less than about 50 percent redifferentiated cells, or more preferably less than about
25 percent redifferentiated cells, or even more preferably less
than about 10 percent redifferentiated cells, or even more
preferably less than about 5 percent redifferentiated cells, or
even more preferably less than about 1 percent redifferentiated cells. "Redifferentiated cells" as used herein, refers to
cells that have terminally differentiated during the performance of the methods herein prior to migration, differentiation and incorporation into host tissue to.
Similar to other embodiments described above, the multipotent stem cells, optionally in cluster form, are administered
by injecting with a syringe, inserting with a catheter or
implanting surgically. The multipotent stem cells can be
administered at the site of neurological or corporal deficit,
systemically (e.g., intravenously), or in the case of neurological deficits of the brain, spinal cord or any tissues accessible
by cerebral spinal fluid (CSF), in a brain ventricle. In other
words, the cells can be implanted to a body cavity that is
fluidly-connected to the area of neurological or corporal deficit or directly to the area of neurological or corporal deficit.
The neurological deficit is optionally caused by a neurodegenerative disease, a traumatic injury, a neurotoxic injury,
ischemia, a developmental disorder, a disorder affecting
vision, an injury or disease of the spinal cord, a demyelinating
disease, an autoimmune disease, an infection, or an inflammatory disease and the corporal deficit is optionally caused
by corporal disease, disorder, injury, trauma, malfunction,
degeneration or loss.
In the methods relating to the in vivo stimulation of proliferation and migration of endogenous and exogenous mam-
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malian stem cells, an effective amount of pyrimidine derivatives is administered. An effective amount can be, for
example, a concentration effective to accomplish aforementioned effects. Non-limiting, exemplary concentrations can
be between about 0.01 mg/kg/day to 50 mg/kg/day, more
preferably between about 0.1 mg/kg/day to 10 mg/kg/day,
even more preferably between about 1 mg/kg/day to 5 mg/kg/
day, and even more preferably about 3 mg/kg/day. The pyrimidine derivatives can be administered as necessary to elicit
the stimulatory effects, an effective period, which can be, for
example, between about 1 and 60 days, or more preferably
between about 1 and 30 days, or more preferably between
about 1 and 15 days, or even more preferably between about
1and10 days, ormorepreferablybetweenabout2 and 7 days,
or even more preferably about 5 days.
The in vivo methods of the disclosure can further comprise
the administration of a growth factor, including, for example,
fibroblast growth factor (FGF), epidermal growth factor
(EGF) or a combination thereof.
The disclosure also provides methods of stimulating proliferation, migration or both proliferation and migration of
mammalian stem cells in vitro. In one embodiment, the
method comprises the step of contacting a mammalian stem
cell or in vitro culture thereof with an effective amount of the
pyrimidine derivative of formulae (I) or (II) above or a pharmaceutically acceptable salt thereof. The stem cell culture
can be contacted with the pyrimidine derivative at a concentration effective to produce the stimulatory effect. For
example, a concentration of between about 50 nM to 1 mM
can be used, or more preferably between about 500 nM to 500
µM, or even more preferably between about 1 µM to 100 µM,
or more preferably between about 5 µM to 75 µMand even
more preferably about 50 µM. As with in vivo embodiments,
the stem cell culture can be contacted with pyrimidine derivatives for an effective period, which can be, for example,
between about 1 and 60 days, or more preferably between
about 1 and 30 days, or more preferably between about 1 and
15 days, or even more preferably between about 1 and 10
days, or more preferably between about 2 and 7 days, or even
more preferably about 5 days. Also similar to the in vivo
embodiments, the cell cultures can be contacted with a
growth factor, for example, FGF, EGF or a combination
thereof. A growth factor, as defined herein, refers to a protein,
peptide or other molecule having a growth, proliferative, or
trophic effect on the cells (whether "more" or "less" developmentally potent as defined herein) or progeny thereof.
Growth factors used for inducing proliferation include any
trophic factor that allows more or less developmentally potent
cells to proliferate, including any molecule that binds to a
receptor on the surface of the cell to exert a trophic, or growthinducing effect on the cell. Exemplary proliferation-inducing
growth factors include epidermal growth factor (EGF),
amphiregulin, acidic fibroblast growth factor (aFGF or FGF1), basic fibroblast growth factor (bFGF or FGF-2), transforming growth factor alpha (TGFcx), and combinations
thereof. Preferred proliferation-inducing growth factors
include EGF and FGF or a combination thereof. Growth
factors are usually added to the culture medium at concentrations of between about 1 fg/mL to 1 mg/mL. Concentrations
between about 1 to 100 ng/mL are usually sufficient. Simple
titration experiments routine in the art are used to determine
the optimal concentration of a particular growth factor for a
particular cell culture (see, e.g., Cutroneo et al., 2000, Wound
Repair Regen, 8: 494-502). The method can, in certain
embodiments, further comprise contacting the multipotent
stem cell culture with heparin.

The disclosure also provides cells that are treated according to provided methods and are thereby stimulated to proliferate, migrate or both proliferate and migrate in vivo or in
vitro. These cells can be used as an active ingredient in a
pharmaceutical composition for treating a neurological deficit or corporal deficit. In certain embodiments, the pharmaceutical composition further comprises a pharmaceutically
acceptable carrier as described below.
Pharmaceutical compositions optimally comprise a therapeutically effective amount of the stimulated cells of disclosed herein in admixture with a pharmaceutically or physiologically acceptable formulation agent selected for
suitability with the mode of administration. Acceptable formulation materials preferably are nontoxic to the stimulated
cells and the recipients at the dosages and concentrations
employed.
The pharmaceutical compositions of the disclosure may
contain formulation materials for modifying, maintaining, or
preserving, for example, pH, osmolarity, viscosity, clarity,
color, isotonicity, odor, sterility, stability, rate of dissolution
or release, adsorption, or penetration of the composition, as
well as proliferation, migration and differentiation capacity
of the stimulated cells of the disclosure. Suitable formulation
materials include, but are not limited to, amino acids (such as
glycine, glutamine, asparagine, arginine, or lysine), antimicrobial compounds, antioxidants (such as ascorbic acid,
sodium sulfite, or sodium hydrogen-sulfite), buffers (such as
borate, bicarbonate, Tris-HCl, citrates, phosphates, or other
organic acids), bulking agents (such as mannitol or glycine),
chelating agents (such as ethylenediamine tetraacetic acid
(EDTA)), complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin), fillers, monosaccharides, disaccharides, and other
carbohydrates (such as glucose, mannose, or dextrins), proteins (such as serum albumin, gelatin, or immunoglobulins),
coloring, flavoring and diluting agents, emulsifying agents,
hydrophilic polymers (such as polyvinylpyrrolidone), low
molecular weight polypeptides, salt-forming counterions
(such as sodium), preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic
acid, or hydrogen peroxide), solvents (such as glycerin, propylene glycol, or polyethylene glycol), sugar alcohols (such
as mannitol or sorbitol), suspending agents, surfactants or
wetting agents (such as pluronics; PEG; sorbitan esters;
polysorbates such as polysorbate 20 or polysorbate 80; triton;
trimethamine; lecithin; cholesterol or tyloxapal), stability
enhancing agents (such as sucrose or sorbitol), tonicity
enhancing agents (such as alkali metal halides-preferably
sodium or potassium chloride--or mannitol sorbitol), delivery vehicles, diluents, excipients and/ or pharmaceutical adjuvants. See REMINGTON'S PHARMACEUTICAL SCIENCES (18th Ed., A. R. Gennaro, ed., Mack Publishing
Company 1990).
The primary vehicle or carrier in a pharmaceutical composition may be either aqueous or non-aqueous in nature. For
example, a suitable vehicle or carrier for injection may be
water, physiological saline solution, or artificial cerebrospinal fluid. Optimal pharmaceutical compositions will be determined by a skilled artisan depending upon, for example, the
intended route of administration, delivery format, desired
dosage and recipient tissue. See, e.g., REMINGTON'S
PHARMACEUTICAL SCIENCES, supra. Such compositions may influence the physical state, stability, and effectiveness of the composition.
Examples of the pharmaceutically acceptable salts of the
compounds of formulae (I) and (II) include hydrochlorides,
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hydrobromides, sulfates, bisulfites, phosphates, acidic phosphates, acetates, maleates, fumarates, succinates, lactates,
tartrates, benzoates, citrates, gluconates, glucanates, methanesulfonates, p-toluenesulfonates and naphthalene-sulfonates which are formed from acids capable of forming
pharmaceutically acceptable anion-containing nontoxic acid
addition salts, hydrates thereof, and quaternary ammonium
(or amine) salts or hydrates thereof. In a preferred embodiments the pyrimidine derivative of formula (I) is 2-piperadino-6-methyl-5-oxo-5,6-dihydro(7H) pyrrolo[2,3-d]pyrimidine maleate (the C4 H4 0 4 maleate salt), also known as
MS-818 (see, for example, Sanyo eta!., 1998, J. NeurosciRes.
54: 604-612). Thus, the disclosure advantageously provides
methods of stimulating proliferation and migration of mammalian stem cells in vivo and in vitro, cells produced by those
methods, pharmaceutical compositions to treat neurological
and corporal deficits, and methods of administering the cells
and pharmaceutical compositions of the disclosure.
Cells can be obtained in any way known in the art and from
any tissue, for example, from donor tissue by dissociation of
individual cells from the connecting extracellular matrix of
the tissue or from commercial sources of NSCs (e.g., BioWhittaker, Walkersville, Md., CC-2599). Tissue from brain
can removed using sterile procedures, and the cells can be
dissociated using any method known in the art including
treatment with enzymes such as trypsin, collagenase and the
like, or by using physical methods of dissociation such as
mincing or treatment with a blunt instrument. Dissociation of
neural cells can be carried out in tissue culture medium; in a
preferred embodiment, the medium for dissociation of juvenile and adult cells is low calcium artificial cerebral spinal
fluid (aCSF) having a formula identical to aCSF (124 mM
NaCl, 5 mM KC!, 1.3 mM MgCl 2 , 2 mM CaCl 2 , 26 mM
NaHC0 3 , and 10 mM D-glucose) except that MgCl 2 is
present at a concentration of3.2 mM and CaCl 2 at a concentration of 0.1 mM. Dissociated cells are centrifuged at low
speed, between 200 and 2000 rpm, usually between 400 and
800 rpm, the suspension medium is aspirated, and the cells are
then resuspended in culture medium. Suspension cultures are
preferred iflarge numbers of undifferentiated neural stem cell
progeny are desired. Cell suspensions are seeded in any
receptacle capable of sustaining cells, preferably culture
plates or roller bottles that inhibit contact-dependent stem cell
differentiation, including uncoated flask or a flask that has
been treated to repel the cells.
While isolation from brain tissue is generally feasible for
preparation of exogenous multipotent cells to be administered with the pyrimidine derivative according to the methods
of the instant disclosure, stem cells from bone marrow (e.g.,
mesenchymal stem cells) are a particularly good source of
cells for generating multi potent stem cells of App. 1, because
isolation techniques are well established in the art having
been used for decades in immune disorder bone marrow
transplants. Further, the methods of the instant disclosure can
then be carried out with autologous cells, thus alleviating any
concerns over immunological rejection. Thus, a patient's own
mesenchymal stem cells can be isolated, treated according to
the methods ofApp. 1 andreadministered where necessary. In
contrast, autologous transplants using a neural cell source,
while certainly not impossible, are not as feasible as, for
example, mesenchymal cells.
Growth of multipotent stem cells under the above culture
conditions induces or permits these cells to form undifferentiated cell clusters. These clusters are optimally grown at a
density ofapproximately 50 clusters per T75 flask in 20 mL of
the growth medium consisting of, for example, DMEM/
HAMS F12 (at about 3:1; Gibco, BR L, Burlington, 0 N),

supplemented with an antibiotic-antimycotic mixture (1: 100,
penicillin G, streptomycin sulfate, amphotericin B; Gibco),
B27 (1:50, GIBCO), humanrecombinantFGF-2 andEGF (20
ng/ml each, R&D Systems, Minneapolis, Minn.) and heparin
(5 µg/mL, Sigma, St. Louis, Mo.). The cultures are kept in a
C0 2 incubator (about 5% C0 2 ) at 3 7° C. To facilitate optimal
growth conditions, clusters of two or more cells are sectioned
into quarters approximately every 14 days and fed by replacing 50% of the medium approximately every 4-5 days. These
conditions permit rapid and continual growth of MSCs that
can be expanded indefinitely while retaining their multi potent
character. As with most eukaryotic cells, conditions for culturing should be as close as possible to physiological conditions. The pH of the culture medium should be close to
physiological pH, preferably between pH 6-8, more preferably between about pH 7 to 7.8, with pH 7.4 being most
preferred. Physiological temperatures range between about
30° C. to 40° C. Cells are preferably cultured at temperatures
between about 32° C. to about 38° C., and more preferably
between about 35° C. to about 37° C. Multipotentneural stem
cells (MNSCs) prepared and maintained as disclosed herein
continue to exhibit multipotent character after more than
three years of serum-free propagation. Treatment with pyrimidine derivative according to the methods of the disclosure
then transform these cells into the cells of the disclosure, cells
specially stimulated for proliferation, migration or both. If in
vitro differentiation is desired, the cells can be replated in
culture dishes in, for example, serum-free basal medium
Eagle (BME), which contains Earle's salt and L-glutamine.
The cells can be cultured for about 5 days in the absence of
FGF-2, EGF or other extrinsic differentiation factors. When
induced to differentiate in this way, these cultured MNSCs
exhibit characteristic morphologies of neurons or astrocytes
when immunohistochemically stained with b-III tubulin (a
neuronal cell marker) or glial fibrillary acidic protein (GFAP,
an astrocyte marker).
MSCs prepared according to the methods of Apps. 1 or 2
and utilized as taught herein that are proliferated in serumfree media are grown in the presence of a substituted deoxyuridine. Examples include a halo-deoxyuridine such as bromodeoxyuridine (BrdU) or iododeoxyuridine (IrdU), or an
alkyl-substituted deoxyuridine such as a methyldeoxyuridine
prior to transplantation into a host. The growth medium used
to generate MSCs according to Apps. 1 and 2 for use in the
present embodiments comprises the components of the longterm propagation media, but also contains an effective
amount of substituted deoxyuridine, for example, concentrations between about 10 nanomolar and 100 micromolar, more
preferably between about 2 and 50 micromolar, and more
preferably about 10 micromolar bromodeoxyuridine. Pretransplantation propagation can extend for an effective
period, for example, between about 1 and 10 days, more
preferably between about 1 and 5 days and more preferably
between about 2 and 3 days.
MSCs prepared according to the methods of Apps. 1 and 2
can be administered according to the instant disclosure to an
animal with abnormal or degenerative symptoms obtained in
any manner, including those obtained as a result of age, physical or biological trauma, or neurodegenerative disease and the
like, or animal models created by man using recombinant
genetic techniques, such as transgenic and "gene knockout"
animals.
Recipients of the MSCs and pyrimidine derivatives according to the methods of the disclosure can be immunosuppressed, either through the use of immunosuppressive drugs
such as cyclosporin, or through local immunosuppression
strategies employing locally applied immunosuppressants,
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but such immunosuppression need not necessarily be a prerequisite in certain immunoprivileged tissues such as, for
example, brain and eye tissues or in the case of autologous
transplantation. In certain embodiments, the delivery method
of the disclosure can cause less localized tissue damage to the
site of cell damage or malfunction than existing methods of
delivery.
MSCs of Apps. 1 and 2 and used herein can be prepared
from the recipient's own tissue. In such instances, the progeny of the more developmentally potent cells can be generated from dissociated or isolated tissue and proliferated in
vitro using the methods described in App. 1, App. 2, and
herein. In the case of mesenchymal stem cells (MeSCs ),
progeny can be generated from MeSCs isolated from, for
example, bone marrow. Upon suitable expansion of cell numbers, the stem cells of Apps. 1 or 2 can be treated and administered according to the instant disclosure into the recipient's
affected tissue.
It is well recognized in the art that transplantation of tissue
into the CNS offers the potential for treatment of neurodegenerative disorders and CNS damage due to injury. Transplantation of new cells into the damaged CNS has the potential to repair damaged circmtnes and provide
neurotransmitters thereby restoring neurological function. It
is also recognized in the art that transplantation into other
tissue, such as eye tissue, offers the potential for treatment of
degenerative disorders and tissue damage due to injury. Apps.
1 and 2 provide methods for generating more developmentally potent MSCs from less developmentally potent MSCs.
The use of the cells of Apps. 1 or 2, or the cells of the instant
disclosure specially stimulated for proliferation, migration or
both in the treatment of neurological disorders and CNS
damage, as well as the use of these MSCs in the treatment of
other tissue damage or degeneration, can be demonstrated by
the use of established animal models known in the art.
There are significant differences in the method of delivery
to the brain and spinal cord of the cells prepared according to
Apps. 1, 2 and the present disclosure, as well as the pyrimidine derivatives described herein, compared to the prior art.
One exemplary difference is that the cells prepared according
to Apps. 1, 2 and the present disclosure are transplanted
intraventricularly. Further, while the transplantation of one or
more separate more cells of Apps. 1, 2 or the instant disclosure is efficacious, such cells are preferably transplanted in
the form of clusters of two or more cells via a surgical procedure, injection using a syringe large enough to leave the
neurosphere-like clusters substantially intact, or insertion by
catheter. The results disclosed in the examples below indicate
that ventricular delivery of the cells ofApps. 1 or 2 or the cells
of the present disclosure in cluster form can result in migration to the area of damage in the brain and proper neuronal
differentiation. Further exemplified below is the effect of a
pyrimidine derivative on the stimulation of proliferation and
migration. Another benefit of intraventricular injection is less
tissue destruction, resulting in less localized recruitment of
immune cells by the host. This is evidenced by the lack of
ventricular distortion, tumor formation, and increased host
astrocyte staining without any immunosuppression.
The method of delivery of the cells of Apps. 1, 2 or the
instant disclosure to the brain can be essentially duplicated
for other immunoprivileged tissue such as, for example, the
eye. Delivery of intact clusters of two or more cells via injection using a syringe large enough to leave the clusters substantially intact can result in migration to the area of damage
in the eye and proper tissue-specific differentiation. Further,
administration of pyrimidine derivatives according to the

methods of the disclosure can substantially increase the proliferation of endogenous and exogenous MSCs.
There are examples in the art of intra-tissue injection
(brain) of dissociated and partially differentiated NSCs (see,
e.g., Benninger et al., 2000, Brain Pathol. 10: 330-341;
Blakemore et al., 2000, Cell Transplant. 9: 289-294; Rosser et
al., 2000, Eur. J. Neurosci. 12: 2405-2413; Rubio et al., 2000,
Mo!. Cell. Neurosci. 16: 1-13). In contrast, the methods of the
instant disclosure employ injection of generally intact clusters because the dissociation of clusters, in the case of neurallineage clusters of cells known as "neurospheres," can cause
immediate senescence and increase the vulnerability ofNSCs
in culture. See, e.g., Svendsen et al., 1998, J. Neurosci. Methods 85: 141-152. As provided by this disclosure, intraventricular transplantation provides an alternative route to sitespecific injection disclosed in the prior art. Using
intraventricular transplantation, grafted cells can gain access
to various structures by the flow of cerebrospinal fluid (CSF),
and transplantation of NSCs prepared according to Apps. 1
and 2 or the present disclosure and administered according to
the present disclosure in cluster form can act to prevent premature differentiation at inappropriate anatomical sites in the
brain and central nervous system. Regarding the eye,
intraocular administration of clusters of NSCs prepared
according to Apps. 1 and 2 or the present disclosure, for
example into the vitreous fluid, allows these multipotent cells
to migrate to the area of degeneration or injury and differentiate appropriately.
Delivery of MSCs of Apps. 1 and 2 and of the present
disclosure into other, non-immunoprivileged tissues can also
be carried out, particularly when the MSCs are autologous to
the recipient.
Functional integration of the graft into the host's neural
tissue can be assessed by examining the effectiveness of
grafts on restoring various functions, including but not limited to tests for endocrine, motor, cognitive and sensory functions. Useful motor tests include tests that quantitate rotational movement away from the degenerated side of the brain,
and tests that quantitate slowness of movement, balance,
coordination, akinesia or lack of movement, rigidity and
tremors. Cognitive tests include tests of the ability to perform
everyday tasks, as well as various memory tests, including
maze performance such as the Morris water maze performance. For example, using the cells and methods of Apps. 1
and 2, MNSCs injected into the ventricle of24-month-oldrats
after in vitro expansion displayed extensive and positional
incorporation into the aged host brain with improvement of
cognitive score (FIG. 1), as assessed by the Morris water
maze after 4 weeks of the transplantation. Results of the
experiments disclosed herein indicate that the aged brain is
capable of providing the necessary environment for MSCs of
Apps. 1 and 2 and the present disclosure to retain their multipotent status and demonstrate the potential for neuroreplacement therapies in age associated neurodegenerative disease.
Functional integration of the graft into the host's other
tissue can be assessed by examining the effectiveness of
grafts on restoring various functions specific to the injured or
degenerated tissue, for example improvement in sight for
transplantation of stem cells of the disclosure to the eye.
Using the methods of the present disclosure, substantial
stimulation of proliferation of endogenous stem cells can be
observed in the eye with administration of a pyrimidine
derivative as disclosed herein.
As assessed by the Morris water maze test, improvement in
spatial memory of MSC-transplanted animals (which cells
were prepared according to Apps. 1 or 2, and apply to the cells
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of the instant disclosure) was accompanied by incorporation
Apps. 1 and 2 and the present disclosure provide methods for
of the MSCs into the brain areas known to be related to spatial
counteracting impaired brain function due to advancing age
memory. The post-transplant morphology of rat brain tissue
through the addition of MSCs (of Apps. 1 and 2 and the
indicates that functional association of the transplanted cells
present disclosure) capable of proliferation, migration and
to the host brain occurs. Immunohistochemical analysis
differentiation in mammalian brain when introduced thereto.
revealed that the bII-tubulin-positive donor-derived cells
Physical trauma and biological trauma are additional
causes of impaired or improper brain function. The term
found in the cerebral cortex are characterized by having den"physical trauma" denotes brain cell damage due to external
drites pointing to the edge of the cortex whereas in the hipsources such as blunt head trauma, severe concussion and the
pocampus, donor-derived neurons exhibited morphologies
with multiple processes and branches. These differential mor- 10 like. Such physical trauma can be localized or general
phologies of the transplanted MSCs in different brain regions
depending on the source and severity of the trauma. The term
"biological trauma" denotes any acute brain injury that has its
indicate that site-specific differentiation of the MSCs occurs
according to various factors present in each brain region.
origin in a biological process, for example, stroke, aneurysm,
Strong astrocyte staining was also found in the frontal
epilepsy, brain tumor, hypoxia and the like.
cortex layer 3 and CA2 region ofhippocampus in rat brains 15
Another source of impaired or improper brain function is
neurodegenerative disease. In recent years neurodegenerative
transplanted with MSCs of Apps. 1 and 2, areas where astrodisease has become an important concern due to an expanding
cytes are not normally present in the animal. Migration of the
more developmentally potent cells to the CA2 is of particular
elderly population that is at greatest risk for these disorders.
interest because CA2 pyramidal neurons highly express
Neurodegenerative diseases include, but are not limited
bFGF, and the expression ofbFGF is up-regulated by entorhi- 20 Alzheimer's disease, amyotrophic lateral sclerosis (ALS),
Parkinson's disease, Pick's disease, Huntington's disease,
nal cortex lesions (see, e.g., Eckenstein et al., 1994, Biochem.
Pharmacol. 47: 103-110; Gonzalez et al., 1995, Brain Res.
progressive supranuclear palsy, corticobasal degeneration,
Parkinson-ALS-dementia complex, Gerstmann-Straussler701: 201-226; Williams et al., 1996, J. Comp. Neural. 370:
Scheinker syndrome, Hallervorden-Spatz disease, Kufs' dis147-158). CA2 pyramidal neurons in the host brain can
express bFGF as a response to a reduction of synaptic trans- 25 ease, Wilson's disease, multiple sclerosis (MS), late-onset
mission, an event that can occur during aging. Subsequently,
metachromatic leukodystrophy and adrenoleukodystrophy.
this expressed bFGF can act as a signal for transplanted MSCs
The effects of these diseases can be counteracted by adminof Apps. 1 and 2 or the present disclosure to respond, migrate
istration of the MSCs of Apps. 1 and 2 and the present disor proliferate under the influence of bFGF produced in the
closure.
30
host brain after the transplantation.
There are a variety of organic brain diseases that impair
motor or cognitive function. Degeneration in the basal ganThe regions rich in astrocyte staining in transplanted rat
brains are the same regions where extensively stained neuglia can lead to diseases with cognitive and motor symptoms,
depending on the exact location of the degeneration. Motor
ronal fibers were identified (FIGS. 2a, 2d and 2e). During
development, glial cells have many complex functions, such
deficits are a common result of degeneration in the basal
as neuronal and axonal guidance and production of trophic 35 ganglia. Huntington's chorea is associated with the degeneration of neurons in the striatum, which leads to involuntary
factors (see, e.g., Pundt et al., 1995, Brain Res. 695: 25-36).
This overlapping distribution of glial and neuronal fibers
jerking movements in the host. Degeneration of a small
strongly suggests that this interaction plays a pivotal role in
region called the subthalamic nucleus is associated with violent flinging movements of the extremities in a condition
survival, migration, and differentiation of the transplanted
MSCs.
40 called ballismus, while degeneration in the putamen and globus pallidus is associated with a condition of slow writhing
Immunohistochemistry of transplanted rat brains reveals a
movements or athetosis. In Parkinson's disease, degeneration
symmetrical distribution of neurons and astrocytes at both
is seen in another area of the basal ganglia, the substantia
sides of the host brain, indicating that the progeny of the more
developmentally potent cells of Apps. 1, 2 (and those of the
nigra par compacta. This area normally sends dopaminergic
present disclosure) can migrate. Although astrocytes have 45 connections to the dorsal striatum, which are important in
regulating movement. Therapy for Parkinson's disease has
been shown to migrate over long distances following transcentered upon restoring dopaminergic activity to this circuit,
plantation (see, e.g., Blakemore et al., 1991, Trends Neurosci.
14: 323-327; Hatton et al., 1992, Glia 5: 251-258; Lundberg
which can be accomplished by transplantation of neural stem
et al., 1996, Exp. Neural. 139: 39-53), there is experimental
cells to this region of the brain according to the instant disevidence showing that neurons do not migrate as widely as 50 closure.
In Alzheimer's disease, another neurodegenerative disglial cells (see, e.g., Fricker et al., 1999, J. Neurosci. 19:
5990-6005). As disclosed herein, cells derived from the
ease, there is substantial cellular degeneration of the forebrain
and cerebral cortex. Further, a localized area of the basal
MSCs of Apps. 1 and 2 possess similar migratory capacity to
astrocyte precursors.
ganglia, the nucleus basalis of Meynert, appears to be selecAs MSCs of Apps. 1 and 2 and the present disclosure can 55 tively degenerated. This nucleus normally sends cholinergic
mimic neural stem cells in many regards, relevant informaprojections to the cerebral cortex, which are thought to partion pertaining to neural stem cells is presented, followed by
ticipate in cognitive functions including memory.
information pertaining to mesenchymal and retinal stem
Mesenchymal Related
cells. One of skill in the art will readily recognize the methods
Although adult stem cells continue to possess some multiof the disclosure are not limited to these three types of stem 60 potency, cell types produced from adult stem cells are limited
cells and instead extend to cover all cell types not yet termiby their tissue-specific character. For example, human NSCs
spontaneously differentiate into brain cells under basal media
nally differentiated.
Neural-Related
conditions, but MeSCs cannot spontaneously differentiate
Due to the generally low proliferation rate of manimalian
into neural cells without the addition of certain factors. These
NSCs, there is a correlation between advancing age and 65 results indicate that each stem cell contains specific informaimpaired brain function even in the absence of specific neution that would allow it to become a special type of cell, i.e.,
rodegenerative disease or physical or biological brain trauma.
they are partially committed to become a particular type of
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cell in a tissue-specific manner. To overcome this barrier of
stem cell lineage, alterations to the cells and their environment are necessary. However, the exact regulation mechanisms of tissue-specific stem cell fate decisions remain
unclear. The absence of this knowledge creates an important
problem, because although MeSCs are rather easy to isolate
from bone marrow and to proliferate in culture, they cannot
naturally differentiate into NSCs or other non-mesenchymallineage cells. Although the potential therapeutic use of
MeSCs in the central nervous system has been discussed,
technologies to induce neural lineage in MeSCs had not been
fully established prior to Apps. 1 and 2. The present provided
is methods stimulating proliferation, migration or both proliferation and migration of the endogenous stem cell population or populations of exogenously introduced cells, such as,
for example, the cells of Apps. 1 or 2.
MeSCs prepared according to the methods of App. 1 can
serve as an alternative to NSCs for potential therapeutic use
utilizing the methods of App. 1 and the present disclosure,
which exploit the capacity of substituted deoxyuridine species, such as BrdU, to prime the MeSCs, i.e., remove them
from their restricted mesenchymal differentiation path to the
neural stem cell-like (or other lineage, i.e., make them more
developmentally potent) differentiation path and pyrimidine
derivatives, which stimulate them to proliferate and migrate
far above wild-type rates. MeSCs were successfully differentiated into neurons and glia in vitro and in vivo using the
substituted deoxyuridine pretreatment of App. 1. Thus,
MeSCs of App. 1 can serve as an alternative to NSCs for
potential therapeutic use in neuroreplacement utilizing the
methods of App. 1 and the present disclosure.
The methods of the instant disclosure are important in the
neuroreplacement field because they enable the expansion of
endogenous stem cell numbers in vivo. Further, the methods
of the disclosure are important in the neuroreplacement field
because they enable the stimulation of proliferation and
migration in exogenously introduced, developmentally
potent, stem cell populations such as those of Apps. 1 or 2.
Since the pyrimidine derivative, as used in the instant disclosure, can be used on various stem cell populations, the disclosure is not only useful to neuroreplacement but to other
kinds of tissue regeneration or replacement as well.
Retinal Related
Retinal degenerative diseases, including macular degeneration, are major causes of blindness. Despite investigations
into gene therapy, growth/survival factor injections and vitamin treatments, no effective vision-restoring treatments are
currently available. Visual impairment caused by the degeneration of photoreceptors or neural cells has been considered
incurable because of a long-held "truism" that neurons do not
regenerate during adulthood. However, this statement has
been challenged and there is new evidence that these cells do
indeed have the potential to be renewed after maturation, thus
opening a door for the development of novel therapies to treat
visual impairment by retinal regeneration using stem cell
transplantation.
The capacity for retinal regeneration in cold-blooded vertebrates has long been recognized. Fish and amphibians continue to make new retinal neurons through a population of
retinal stem cells residing at the peripheral margin of the
retina, the so-called "ciliary marginal zone." Recent studies
have provided evidence that birds and adult mammals also
possess a zone of cells at the retinal margin analogous to the
ciliary marginal zone of cold-blooded vertebrates. These retinal stem cells are reported not only to generate photoreceptor
and other retinal cells in vitro, but also to differentiate into
retinal cells following transplantation into the retinal area.

Although these results indicate the possibility of retinal
regeneration therapy, an alternative source of stem cells, or a
means to increase the number of endogenous retinal stem
cells, is required for clinical applications because the number
of retinal stem cells is limited.
Neural stem cells have been isolated from embryonic and
adult mammalian brains and have been propagated in vitro in
a variety of culture systems. Using a serum-free unsupplemented media condition, NSCs spontaneously differentiated
into bII-tubulin-, glial fibrillary acidic protein (GFAP)-, and
04-immunopositive cells, markers for neurons, astrocytes,
and oligodendrocytes, respectively. MSCs treated according
to methods of Apps. 1 and 2 migrate and differentiate into
neurons and glia after transplantation into the brains of
24-month-old rats and significantly improved the cognitive
functions of these animals. This result suggested that MSCs
produced according to Apps. 1 and 2 could provide transplantable material to produce a retinal stem cell alternative.
There are variety of factors involved in the development of
retinal tissue that regulate the proliferation and differentiation
of retinal cells. Transforming growth factor beta 3 (TGF-b3)
is thought to regulate cell proliferation during development
and also influence the commitment or the differentiation, or
both, of neural progenitor cells to retinal fates. Treatment of
embryonic day-18 rat retinal cultures with TGF beta-like
protein, activinA, causes the progenitor cells in these cultures
to exit the cell cycle and differentiate into rod photoreceptors,
indicating that the TGF family is an important regulator of
photoreceptor differentiation in the developing retina. Treatment of the NSCs prepared according to Apps. 1 and 2 can be
induced to adopt a retinal differentiation path through exposure to the above factors. Utilizing the methods and reagents
of the present disclosure, both exogenous MSCs, like those
prepared according to Apps. 1 and 2, and endogenous stem
cells of the eye can be stimulated to proliferate and migrate
beyond wild-type levels.
Previous transplantation studies ofNSCs into retinal tissue
with rd mice (a model of retinitis pigmentosa), mechanical
lesions, transient ischemia and normal retina have revealed
that donor cells migrate into the retinal area and differentiate
into neurons and glia, but they did not show any retinal cell
markers. These results indicated that NSCs are already committed to become neural tissue, and that this commitment is
not mutable solely by transplantation into the retina. Thus, to
differentiate NSCs (or cells of alternate origin, such as
MeSCs) into retinal cells, alteration of their epigenetic information before retinal transplantation appeared necessary,
something accomplished by the methods of Apps. 1 and 2.
Using the methods of Apps. 1 and 2, NSCs or easily obtainable MeSCs, i.e., can be transformed into MSCs and subsequently used as alternatives to retinal stem cells to repair
ocular tissue damage or promote tissue regeneration. Treatment of endogenous multipotent stem cells populations in
vivo or the multipotent stem cells of Apps. 1 or 2 in vitro
according to the methods of the present disclosure, can
enhance their number and/or migration and hence increase
their efficacy in repairing damaged tissue in the eye.
The inventive methods ofApps. 1 and 2 use BrdU and other
substituted deoxyuridines to change the cell fate decisions of
stem cells. In the case ofretinal transplants, these MSCs are
treated with TGF-b3 to encourage their commitment change
into the various cell types found in eye tissue, inter alia,
chorid, Buchs and retinal pigment epithelium cells, rod and
cone photoreceptor cells, horizontal cells, bipolar neurons,
amacrine, ganglion and optic nerve cells
These non-limiting, exemplary cell types found in eye
tissue are collectively referred to as retinal cells. These results
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are enhanced by the methods of the present disclosure
wherein the number of MSCs competent to migrate and differentiate appropriately is increased due to stimulated proliferation.
There are a variety of neurological and corporal deficits
that can be addressed using the MSCs ofApps. 1 and 2 and the
present disclosure.
"Neurological Deficits" Amenable to Treatment
Because the disclosure relates in part to the discovery that
multipotent precursor cells can be stimulated to proliferate
and migrate through the brain and other tissues, such MSCs
can be used to treat neurological deficits caused by a wide
variety of diseases, disorders, and injuries. These insults
include, but are not limited to, the following.
Degenerative Diseases
Degenerative diseases that can be treated according to the
methods of the disclosure include Alzheimer's disease (AD),
Parkinson's disease (PD), Huntington's disease (HD), Pick's
disease, progressive supranuclear palsy (PSP), striatonigral
degeneration, cortico-basal degeneration, childhood disintegrative disorder, olivopontocerebellar atrophy (OPCA;
including a heritable form), Leigh's disease, infantile necrotizing encephalomyelopathy, Hunter's disease, mucopolysaccharidosis, various leukodystrophies (such as
Krabbe's disease, Pelizaeus-Merzbacher disease, and the
like), amaurotic (familial) idiocy, Kuf's disease, SpielmayerVogt disease, Tay Sachs disease, Batten disease, JanskyBielschowsky disease, Reye's disease, cerebral ataxia,
chronic alcoholism, beriberi, Hallervorden-Spatz syndrome,
and cerebellar degeneration.
Traumatic and Neurotoxic Injuries to the Central Nervous
System
Traumatic and neurotoxic injuries that can be treated
according to the methods of the disclosure include gunshot
wounds, injuries caused by blunt force, injuries caused by
penetration injuries (e.g., stab wounds), injuries caused in the
course of a surgical procedure (e.g., to remove a tumor or
abscess from the CNS or to treat epilepsy), poisoning (e.g.,
with MPTP or carbon monoxide), shaken-baby syndrome,
adverse reactions to medication (including idiosyncratic
reactions), drug overdose (e.g., from amphetamines), and
post-traumatic encephalopathy.
Ischemia
Any disruption of blood flow or oxygen delivery to the
nervous system can injure or kill cells, including neurons and
glial cells, therein. These injuries can be treated according to
the methods of the present disclosure and include injuries
caused by a stroke (including a global stroke (as may result
from cardiac arrest, arrhythmia, or myocardial infarction) or
a focal stroke (as may result from a thrombus, embolus,
hemorrhage, or other arterial blockage)), anoxia, hypoxia,
partial drowning, myoclonus, severe smoke inhalation, dystonias (including heritable dystonias ), and acquired hydrocephalus.
Developmental Disorders
Developmental disorders that can be treated according to
the methods of the disclosure include schizophrenia, certain
forms of severe mental retardation, cerebral palsy (whether
caused by infection, anoxia, premature birth, blood type
incompatibility: etc. and whether manifest as blindness, deafness, retardation, motor skill deficit, etc.), congenital hydrocephalus, metabolic disorders affecting the CNS, severe
autism, Down Syndrome, LHRH/hypothalamic disorder, and
spina bifida.
Disorders Affecting Vision
Disorders affecting vision, particularly those caused by the
loss or failure of retinal cells, can be treated according to the

methods and cells of the disclosure. These disorders include,
for example, diabetic retinopathy, serious retinal detachment,
retinal damage associated with glaucoma, traumatic injury to
the retina, retinal vascular occlusion, macular degeneration
(wet or dry), post-surgical healing, tumor, heritable retinal
dystrophies, optic nerve atrophy, and other retinal degenerative diseases. Cells targeted for repair utilizing cells and
methods of the disclosure include, for example, choroids,
Buchs, retinal pigment epithelial (RPE), rods, cones, horizonta! cells, bipolar neurons, amacrine, ganglion, and optic
nerve.
Injuries and Diseases of the Spinal Cord
Injuries to or diseases affecting the spinal cord can also be
treated according to the methods of the disclosure. Such
injuries or diseases include post-polio syndrome, amyotrophic lateral sclerosis, nonspecified spinal degeneration,
traumatic injury (such as those caused by automobile or
sporting accidents), including any injury that crushes, partially severs, completely severs, or otherwise adversely
affects the function of cells in the spinal cord), injuries caused
by surgery to the spinal cord (e.g., to remove a tumor), anterior horn cell disease, and paralytic diseases.
Demyelinating or Autoimmune Disorders
Neurological deficits caused by demyelination or an
autoimmune response can be treated according to the methods of the disclosure. Such deficits can be caused by multiple
sclerosis, or lupus.
Infectious or Inflammatory Diseases
Neurological deficits caused by an infection or inflammatory disease can be treated according to the methods of the
disclosure. Infections or inflammatory diseases that can cause
treatable deficits include Creutzfeldt-Jacob disease and other
slow virus infectious diseases, AIDS encephalopathy, postencephalitic Parkinsonism, viral encephalitis, bacterial meningitis and meningitis caused by other organisms, phlebitis
and thrombophlebitis of intracranial venous sinuses, syphilitic Parkinsonism, and tuberculosis of the CNS.
In addition to the deficits, diseases and disorders set forth
explicitly above, those of ordinary skill in the art are well able
to recognize neurological deficits, regardless of their cause,
and to apply the methods of the present disclosure to treat
patients who have such deficits. In addition to the conditions
listed above, that are amenable to treatment with the methods
described herein, neurological deficits can be caused by
Lesch-Nyhan syndrome, myasthenia gravis, various dementias, numerous parasitic diseases, and epilepsy. Further, alleviation of age-related memory loss is an object of the disclosure. The methods of the disclosure can be readily applied to
alleviate neurological deficits caused by these and other diseases, disorders, or injuries.
"Corporal Deficits" Amenable to Treatment
The disclosure also relates to the amelioration of corporal
deficits utilizing multipotent precursor cells stimulated to
divide, migrate through damaged tissue and differentiate in a
tissue-specific manner. Cells according to the disclosure can
be used to treat corporal deficits caused by a wide variety of
diseases, disorders, and injuries, the result of which is trauma,
malfunction, degeneration or loss of muscle such as, for
example, cardiac muscle due to myocardial infarction. Other
examples include malfunction, degeneration or loss of other
cells and tissues apart from those discussed in the neurological deficit section above such as, for example, internal organs.
For example, liver function can be adversely affected by,
among other things, disease (e.g., cirrhosis or hepatitis),
trauma or age. Other exemplary internal organs amenable to
treatment utilizing the embodiments of the disclosure include
heart, pancreas, kidney, stomach, and lung. Corporal deficits
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also comprise malfunction, degeneration or loss of skeletal
assets such as, for example, vertebrae.
An advantage of the cells of the disclosure is that they can
be genetically engineered according to routine procedures
known in the art (See, e.g., Sambrook et al., 2001, MOLECULAR CLONING: A LABORATORY MANUAL. 3rd ed.,
Cold Spring Harbor Laboratory Press: N.Y.). In certain
embodiments, constructs encoding proteins of interest can be
provided to the cells. In other embodiments, constructs that
inhibit expression of undesired proteins can be provided
(such as, for example, ribozymes and antisense molecules). In
further embodiments, drug resistance genes and markers, or
detectable markers such as GFP can be provided. Preferably,
the marker and other genes are operably and genetically
linked to gene expression regulatory elements (including but
not limited to promoters and enhancers) that are operable in a
terminally differentiated cell derived from the MNSCs of the
disclosure or in the undifferentiated MNSCs of the disclosure
or both.
The following examples are presented in order to more
fully illustrate the preferred embodiments of the disclosure.
They should in no way be construed, however, as limiting the
scope of the disclosure, as defined by the appended claims.

plantation of treated human NSCs. It is possible that the
physical strength of these animals deteriorated during the
experimental period.
These behavioral results indicate the beneficial effects of
the transplantation ofBrdU-treated human NSCs into the host
brain. After the second water maze task, postmortem brains
were further analyzed by immunohistochemistry for human
bII-tubulin and human GFAP, markers for neurons and astrocytes respectively. There was no sign of ventricular distortion,
no evidence of tumor formation, and no strong host anti-graft
immunoreactivity was observed as revealed by weak host
astrocyte staining. Intensely and extensively stained with
bIII-tubulin, neurons with BrdU-positive nuclei were found
in bilateral singular and parietal cortexes (FIG. 2a-c) and
hippocampus (FIG. 2d,e). The bIII-tubulin-positive neurons
found in the cerebral cortex were typified by a dendrite pointing to the edge of the cortex. In the hippocampus, donorderived neurons exhibited multiple morphologies, varying in
cellular size and shape, and one or more processes and
branching.
Generally, GFAP-positive astrocytes were localized near
the area where neuronal cells were found. On further analysis
(overlapping images of their distributions), donor-derived
astrocytes were found to co-localize with neuronal fibers in
the cortex (FIG. 2j). These astrocytes were larger than the host
glia, with cell bodies 8-10 microns in diameter and thick
processes. Some of these astrocytes had a unilateral morphology (asymmetric), and the immunostaining formed a thin ring
around the nucleus, while the majority of the processes were
formed on the other side. Most cells appeared a symmetrical
with processes forming from all sides. The absence of this
type of cell in normal animal without the transplantation of
treated human NSCs was confirmed using immunohistochemistry for rat astrocytes. Host astrocytes had small cell
bodies with multiple delicate processes, and were distributed
throughout the brain mainly in white matter and around the
edges of the brain.
These results demonstrated that transplanted cells ofApps.
1 and 2 migrated in rat brain and differentiated into appropriate cell types. The concomitant improvement in cognitive
function indicated that transplanted MSCs of Apps. 1 and 2
were functionally integrated into the recipient brains.
The Morris Water Maze:
The Morris water maze consists of a large circular tank
(diameter, 183 cm; wall height, 58 cm), filled with water (27°
C.) and opacified by the addition of powdered milk (0.9 kg).
Beneath the water surface (1 cm) nearthe center of one of the
four quadrants of the maze a clear escape platform (height,
34.5 cm) is positioned. The rats receive three training trials
per day for seven consecutive days, using a 60 sec inter-trial
interval. A training trial consists of placing the animal in the
water for 90 seconds or until the swimming rat successfully
locates the platform. If the rat fails to find the platform within
the 90 seconds, the animal is gently guided to the platform.
For spatial learning assessment, the platform's location
remains constant in one quadrant of the maze, but the starting
position for each trial is varied. Every sixth trial is a probe
trial, during which the platform is retracted to the bottom of
the pool for 30 sec and then raised and made available for
escape. The training trials assess the acquisition and day-today retention of the spatial task while the probe tests are used
to assess search strategy. At the completion of a spatial learning assessment, one session with six trials of cue training is
performed Rats are trained to escape to a visible black platform that is raised 2 cm above the surface of the water. The
location of the platform is varied from trial to trial to assess
sensorimotor and motivational functioning independent of
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EXAMPLES
Example 1
Improvement of Cognitive Function in Aged Rat by the
Transplantation ofNSCs
Human NSCs do not require any exogenous factors for
differentiation and survived more than three weeks in basal
media without the addition of any factor to support their
survival (Qu et al., 2001, Neuroreport 12: 1127-32). Thus, it
appears that human NSCs produce factors to differentiate and
support themselves, which suggested that these cells could be
transplanted into aged animals after treatment according to
the methods of Apps. 1, 2 and the present disclosure.
Human NSCs, expanded without differentiation under the
influence of mitogenic factors in supplemented serum-free
media and pre-treated by the incorporation of bromodeoxyuridine (BrdU) into the nuclear DNA, were injected into the
lateral ventricle of mature (6-month-old) and aged (24month-old) rats. Human NSCs prepared according to the
methods of the disclosure survived 30 days after xenotransplantation into aged rat brain, while retaining both multipotency and migratory capacity, and also improved cognitive
function in 24-month-old rats. Cognitive function of the animals was assessed by the Morris water maze both before and
four weeks after the transplantation of human NSCs of the
disclosure. Before human NSC transplantation, some aged
animals (aged memory unimpaired animals) cognitively
functioned in the range of mature animals, while others (aged
memory impaired animals) functioned entirely out of the
cognitive range of the mature animals. After transplantation
of the BrdU-treated human NSCs, most aged animals had
cognitive function in the range of the mature animals. Strikingly, one of the aged memory-impaired animals showed
dramatic improvement in its behavior, functioning even better
than the mature animals (FIG. la). Statistical analysis showed
that cognitive function was significantly improved in both
mature and aged memory-impaired animals but not in aged
memory-unimpaired animals after BrdU-treated human NSC
transplantation (FIG. lb), which may be due to the physical
limitations of the aged animals. The performance of three of
the aged animals deteriorated in the water maze after trans-
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spatial learning ability. Each rat is given 30 seconds to reach
the platform and is allowed to remain there briefly before the
30 second inter-trial interval. Accuracy of performance is
assessed using a learning index score computed from the
probe trials. The learning index is a derived measure from
average proximity (cumulative search error divided by the
length of the probe trial) on the second, third, and fourth
interpolated probe trials. Scores from these trials are
weighted and summed to provide an overall measure of spatial learning ability. Lower scores on the index indicate a more
accurate search near the target location; higher scores indicate
a more random search and poor learning.
Cell Migration and Differentiation:
In order to investigate differentiation and/or migration of
the cells of Apps. 1 or 2 in the brain, MSCs of those applications were transplanted into rodent brain. The animals were
anesthetized with 50 mg/kg pentobarbital (i.p.) and mounted
in a stereotaxic apparatus (David Kopf). Approximately
lxlO.sup.4 to lxlO.sup.5 cells in 5 µA phosphate-buffered
saline were injected into the ventricle using a microsyringe
attached to the stereotaxic apparatus. After removing the hair
from the surgical site using electric razor, an iodine swab was
be applied to the area and a 0.5 cm surgical incision was made
caudal to rostral in the skin at the surface of the cranium. The
ventricle was stereotaxically localized using the following
exemplary coordinates: AP=-0.58 mm from bregma, ML=+ 1
mm, and 2.4 mm below dura (for mouse): AP=-1.4 mm from
bregma, ML=+3.3 mm, and 4.5 mm below dura (for rat). A
0.4-mm hole was made in the cranium by careful drilling. The
cells of Apps. 1 or 2 were injected into the ventricle using a
microsyringe. The injection was delivered over a period of
five minutes and the needle was left in place for an additional
two minutes following the injection. After the injection, the
surgically incised skin was closed by Michel suture clip (2.5x
1.75 mm). Ten days post-surgery, proper healing of the incision site was observed, and the Michel sutures were removed.
The existence and location of the cells of Apps. 1 or 2 after
administration in rat brain was analyzed as follows. At 30
days post-transplantation, the rats were sacrificed by an overdose of sodium pentobarbital (70 mg/kg, i.p.) and perfused
with phosphate buffered saline (PBS) followed by 4%
paraformaldehyde. Brains were removed and incubated overnight in 4% paraformaldehyde fixative containing 20%
sucrose. The brains were sliced into 20 micron coronal sections using a cryomicrotome. The sections were washed
briefly in PBS and pretreated with IM HCl for 30 minutes at
room temperature and neutralized with sodium borate (0.1 M,
pH 8.0) for 30 minutes in order to increase the accessibility of
an anti-BrdU antibody to BrdU incorporated in the cell
nuclei. After rinsing with PBS, sections were transferred to a
solution containing 0.25% Triton X-100 in PBS (PBST) for
30 minutes. The sections were then blocked by incubation in
PBST containing 3% donkey normal serum for 1 hour, followed by incubating the sections overnight at 48° C. with
sheep anti-BrdU ( 1: 1000; Jackson IR Laboratories, Inc. West
Grove, Pa.) or mouse anti-BrdU (1 :200; DSHB, Iowa City,
Iowa) diluted in PBST. After rinsing the sections in PBS,
donkey anti-mouse or donkey anti-sheep conjugated to
rhodamine IgG (Jackson IR Laboratories, Inc.) was added at
a 1:200 dilution in PBST and the sections further incubated
for 2 hours at room temperature in the dark.
The transplanted cells of Apps. 1 or 2, with BrdU immunopositive nuclei, were stained for human bIII-tubulin and
human glial filament protein (GFAP). The sections were then
washed with PBS and incubated with mouse IgG2b monoclonal anti-human bIII-tubulin, clone SDL3D10 (1:500,
Sigma), goat antihuman GFAP, N-terminal human affinity

purified (1:200, Research Diagnostics Inc., Flander, N.J.) or
mouse IgGl monoclonal anti-GFAP, clone G-A-5 (1:500,
Sigma), respectively, overnight at 48° C. in the dark. After
brief washing with PBS to remove excess primary antibody,
the location of primary antibody binding was then determined
using FITC-conjugated (Jackson IR Laboratories, Inc.) secondary antibody (donkey anti-mouse (1:200) or donkey antigoat IgG (H+L; 1:200), respectively) by incubating the sections for 2 hours at room temperature in the dark.
The sections were then washed with PBS thoroughly
before mounting to glass slides. The mounted sections were
covered with Vectashield using
4',6-diamidine-2phenylindole.2HC1 (DAPI, Vector Laboratories, Inc., Burlingame, Calif.) for fluorescent microscopic observation. Microscopic images were taken by using anAxiocam digital camera
mounted on the Axioscope 2 with Axiovision software
(Zeiss).
NSC Culture:
NSCs were purchased (Bio Whittaker, Walkersville, Md.),
and alternatively isolated from human tissue, and cultured in
a nonsupplemented, serum-free basal medium comprising
HAMS-F12 (Gibco, B R L, Burlington, 0 N); antibioticantimycotic mixture (1:100, Gibco ); B27 (1:50, Gibco );
human recombinant FGF-2 and EGF (20 ng/ml each, Rand D
Systems, Minneapolis, Minn.) and heparin (5 µg/ml, Sigma,
St. Louis, Mo.). The cells were incubated at about 37° C. in a
5% C0 2 humidified incubation chamber (Fisher, Pittsburgh,
Pa.). To facilitate optimal growth conditions, NSC clusters
were sectioned into quarters every 2 weeks and fed by replacing 50% of the medium every 4-5 days. To inhibit differentiation, the cells can be propagated on an uncoated flask or a
flask that has been treated to repel the cells. To induce differentiation, these cells can be replated in the culture dishes
(about lxlO.sup.5 per dish) in the serum-free basal medium
Eagle (BME), which comprises Earle's salt and L-glutamine,
and cultured for about 5 days in the absence of FGF-2 and
EGF and without the addition of other extrinsic differentiation factors. NSCs cultured in this serum-free medium can
spontaneously undergo differentiation into neuronal cell
types.
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Increase of Endogenous Stem Cell Proliferation by a Pyrimidine Derivative
To investigate the effect ofMS-818, a pyrimidine derivative, on stem cell population in vivo, MS-818 (3 mg/kg/day,
i.p.) was injected for 5 days into aged (27-month old) male
Fisher 344 rats. The same volume of saline was injected into
control animals. Bromodeoxyuridine (BrdU) (100 mg/kg/day
i.p.) was then injected for 3 days. Twenty-four hours afterthe
last injection, the brains were removed and fixed for immunohistochemical detection of the proliferating cells by immunostaining for BrdU. The number of BrdU positive cells
increased more than seven fold in the cerebral cortices of
MS-8,8-treated animals compared to those of controls (FIG.
3a, b, e), indicating an increased neural stem cell population in
the brain. In the area of the subventricular zone, a significant
increase not only in the proliferation but also in the migration
of stem cells was found (FIG. 3c, d). When this compound was
injected directly into the vitreous cavity (10 µg one time
injection), a dramatic increase in the number of BrdU-positive cells was found in the retinal ciliary marginal zone (FIG.
4) after three days.
It should be understood that the foregoing disclosure
emphasizes certain specific embodiments of the invention
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and that all modifications or alternatives equivalent thereto
are within the spirit and scope of the invention as set forth in
the appended claims.

-continued

What is claimed is:
1. A method of improving vision by stimulating proliferation, migration or both proliferation and migration of endogenous mammalian retinal stem cells in a mammal in need
thereof, the method comprising administering an effective
amount of a pyrimidine derivative of formula (1) or (2), or a
pharmaceutically acceptable salt thereof, for an effective
period to the manmial,
(1)
2

R9c;i
R

y

R3-N

N

0

~

Nr\X
\_j

and

(2)

10

wherein Rl to RS independently represent a hydrogen atom,
a lower alkyl group, CH 3 0CH 2 CH 2 - , CH 2 CONH 2 ,
--COCH 3 , --COC 2 H5 or --CH 2 0COC2 H5 , and X represents NH, N--CH 3 , N-C 2 H5 , N-ph, N-COOC 2 H5 ,
15 N-S0 2 CH 3 , CH 2 , CHCH 3 , CHC2 H 5 , ---0- or - S - in
which ph stands for a phenyl group.
2. The method of claim 1, wherein the pyrimidine derivative is 2-piperadino-6-methyl-5-oxo-5,6-dihydro-(7H) pyrrole-[3,4-d]pyrimidine maleate (MS-818).
3. The method of claim 1, wherein the pyrimidine deriva20
tive is 2-piperadino-6-methyl-5-oxo-5,6-dihydro-(7H) pyrrole-[2,3-d]pyrimidine maleate.
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